Cargando…
Global research output in ‘pharmacovigilance’ during 2010–2020
The rapid spread of Covid-19 pandemic globally has thrust drugs safety into the spotlight and the public is now more aware of the role of healthcare professionals and health regulators. The present study aimed to measure the global research landscape on pharmacovigilance (PV) indexed in Scopus datab...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673929/ https://www.ncbi.nlm.nih.gov/pubmed/34972583 http://dx.doi.org/10.1016/j.therap.2021.11.011 |
_version_ | 1784615541409841152 |
---|---|
author | Tyagi, Sunil |
author_facet | Tyagi, Sunil |
author_sort | Tyagi, Sunil |
collection | PubMed |
description | The rapid spread of Covid-19 pandemic globally has thrust drugs safety into the spotlight and the public is now more aware of the role of healthcare professionals and health regulators. The present study aimed to measure the global research landscape on pharmacovigilance (PV) indexed in Scopus database for eleven years period spanning from 2010–2020. The study has sought to use quantitative and visualization technologies for data analysis and interpretation. The search strategy accumulated a total of 2052 global publications data on PV. The findings disclose that the global research productivity on PV registered 8.74% average growth rate (AGR) and 7.38% compound average growth rate (CAGR). The mean relative growth rate (RGR) and doubling time (DT) of PV global publications for the 11 years is 0.27 and 3.03, respectively. The average number of authors per paper (AAPP) is 1.52 and average productivity per author (PPA) is 0.68. The authorship patterns in PV research shows collaborative trend as most of the publications have been published by multiple authors (80.75%). The mean values of degree of collaboration (DC), collaboration index (CI), collaboration coefficient (CC) and modified collaboration coefficient (MCC) during the selected period of study are 0.79, 2.74, 0.72, and 0.73, respectively which highly significant and indicates the better authorship collaborations. France is the bellwether in PV related scientific research as produced the highest number of publications. |
format | Online Article Text |
id | pubmed-8673929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86739292021-12-16 Global research output in ‘pharmacovigilance’ during 2010–2020 Tyagi, Sunil Therapie Pharmacovigilance The rapid spread of Covid-19 pandemic globally has thrust drugs safety into the spotlight and the public is now more aware of the role of healthcare professionals and health regulators. The present study aimed to measure the global research landscape on pharmacovigilance (PV) indexed in Scopus database for eleven years period spanning from 2010–2020. The study has sought to use quantitative and visualization technologies for data analysis and interpretation. The search strategy accumulated a total of 2052 global publications data on PV. The findings disclose that the global research productivity on PV registered 8.74% average growth rate (AGR) and 7.38% compound average growth rate (CAGR). The mean relative growth rate (RGR) and doubling time (DT) of PV global publications for the 11 years is 0.27 and 3.03, respectively. The average number of authors per paper (AAPP) is 1.52 and average productivity per author (PPA) is 0.68. The authorship patterns in PV research shows collaborative trend as most of the publications have been published by multiple authors (80.75%). The mean values of degree of collaboration (DC), collaboration index (CI), collaboration coefficient (CC) and modified collaboration coefficient (MCC) during the selected period of study are 0.79, 2.74, 0.72, and 0.73, respectively which highly significant and indicates the better authorship collaborations. France is the bellwether in PV related scientific research as produced the highest number of publications. Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022 2021-12-15 /pmc/articles/PMC8673929/ /pubmed/34972583 http://dx.doi.org/10.1016/j.therap.2021.11.011 Text en © 2021 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Pharmacovigilance Tyagi, Sunil Global research output in ‘pharmacovigilance’ during 2010–2020 |
title | Global research output in ‘pharmacovigilance’ during 2010–2020 |
title_full | Global research output in ‘pharmacovigilance’ during 2010–2020 |
title_fullStr | Global research output in ‘pharmacovigilance’ during 2010–2020 |
title_full_unstemmed | Global research output in ‘pharmacovigilance’ during 2010–2020 |
title_short | Global research output in ‘pharmacovigilance’ during 2010–2020 |
title_sort | global research output in ‘pharmacovigilance’ during 2010–2020 |
topic | Pharmacovigilance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673929/ https://www.ncbi.nlm.nih.gov/pubmed/34972583 http://dx.doi.org/10.1016/j.therap.2021.11.011 |
work_keys_str_mv | AT tyagisunil globalresearchoutputinpharmacovigilanceduring20102020 |